Studi Pendahuluan Pengembangan Vaksin DNA Menggunakan Gen Nukleoprotein Virus SARS-COV-2
##plugins.pubIds.doi.readerDisplayName##
https://doi.org/10.24843/bulvet.2023.v15.i05.p37
Abstrak
Vaksin DNA telah menjadi bidang penelitian yang menarik dalam upaya melawan penyakit infeksius pada hewan. Vaksin DNA adalah formulasi vaksin yang menggunakan fragmen DNA sebagai antigen. DNA pada vaksin mengandung informasi genetik yang diambil dari agen penyakit, seperti virus atau bakteri, yang ingin ditargetkan. Penelitian ini bertujuan untuk mengembangkan vaksin DNA pada hewan dan manusia. Metode penelitian menggunakan klon plasmid DNA dengan gen nukleoprotein virus Covid-19 yang ditransformasikan pada bakteri E. coli stellar. Pengujian titer antibodi vaksin pada mencit dilakukan dengan uji Enzyme-linked immunosorbent assay. Hasil penelitian menunukkan klon plasmid DNA dengan gen nukleoprotein virus SARS-Cov-2 dapat dikembangkan dan dibuktikan. Pemberian klon plasmid DNA dengan gen nukleoprotein pada mencit dapat menginduksi terbentuknya antibodi spesifik terhadap nukleoprotein virus SARS-Cov-2. Pemberian plasmid rekombinan pcDNA-Nukleoprotein terbukti menginduksi terbentuknya antibodi terhadap nukleoprotein yang meningkat dari minggu ke-1 sampai minggu ke-4 dan ke-5 yang kemudian menurun pada minggu ke 6 pasca vaksinasi.
##plugins.generic.usageStats.downloads##
##plugins.generic.usageStats.noStats##
Referensi
Burhan E, Prasenohadi P, Rogayah R, Isbaniyah F, Reisa T, Dharmawan I. 2020. Clinical progression of COVID-19 patient with extended incubation period, delayed RT-PCR time-to-positivity, and potential role of chest CT-scan. Acta Med. Indon. 52: 80-83.
Gu J, Korteweg C. 2007. Pathology and pathogenesis of severe acute respiratory syndrome. Am. J. Pathol. 170: 1136-1147.
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. 2020. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil. Med. Res. 7: 11.
Harris PE, Brasel T, Massey C, Herst CV, Burkholz S, Lloyd P, Blankenberg T, Bey TM, Carback R, Hodge T, Ciotlos S, Wang L, Comer JE, Rubsamen RM. 2021. A synthetic peptide CTL vaccine targeting nucleocapsid confers protection from SARS-CoV-2 challenge in rhesus macaques. Vaccines. 9(5): 520.
Inoue H, Nojima H, Okayama H. 1990. High efficiency transformation of Escherichia coli with plasmids. Gene. 96: 23-28.
Jeewandara C, Aberathna IS, Pushpakumara PD, Kamaladasa A, Guruge D, Wijesinghe A, Gunasekera B, Ramu ST, Kuruppu H, Ranasinghe T, Dayarathna S, Dissanayake O, Gamalath N, Ekanayake D, Jayamali J, Jayathilaka D, Dissanayake M, Jayadas TT, Mudunkotuwa A, Somathilake G, Harvie M, Nimasha T, Danasekara S, Wijayamuni R, Schimanski L, Rijal P, Tan TK, Dong T, Townsend A, Ogg GS, Malavige GN. 2022. Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine. Immun. Inflam. Dis. 10: e621.
Kiros M, Andualem H, Kiros T, Hailemichael W, Getu S, Geteneh A, Alemu D, Abegaz WE. 2020. COVID-19 pandemic: current knowledge about the role of pets and other animals in disease transmission. Virol. J. 17: 143.
Liu DX, Fung TS, Chong KK, Shukla A, Hilgenfeld R. 2014. Accessory proteins of SARS-CoV and other coronaviruses. Antiviral. Res. 109: 97-109.
Liu J, Chang W, Pan L, Liu X, Su L, Zhang W, Li Q, Zheng Y. 2018. An Improved method of preparing high efficiency transformation Escherichia coli with both plasmids and larger DNA fragments. Indian J. Microbiol. 58: 448-456.
Liu YC, Kuo RL, Shih SR. 2020. COVID-19: The first documented coronavirus pandemic in history. Biomed J. 43(4):328-333.
Omma A, Batirel A, Aydin M, Yilmaz Karadag F, Erden A, Kucuksahin O, Armagan B, Guven SC, Karakas O, Gokdemir S, Altunal LN, Buber AA, Gemcioglu E, Zengin O, Inan O, Sahiner ES, Korukluoglu G, Sezer Z, Ozdarendeli A, Kara A, Ates I. 2022. Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Turkiye: A randomized trial. Hum. Vac. Immunother. 18: 2122503.
Putra A, Widyatmoko A, Ibrahim S, Amansyah F, Amansyah F, Berlian MA, Retnaningsih R, Pasongka Z, Sari FE, Rachmad B. 2021. Case series of the first three severe COVID-19 patients treated with the secretome of hypoxia-mesenchymal stem cells in Indonesia. F1000 Res. 10: 228.
Santi T, Sungono V, Kamarga L, Samakto B, Hidayat F, Hidayat FK, Satolom M, Permana A, Yusuf I, Suriapranata IM, Jo J. 2022. Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia. Clin. Exp. Vac. Res. 11: 209-216.
Sharma O, Sultan AA, Ding H, Triggle CR. 2020. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front. Immunol. 11: 585354.
Skariyachan S, Challapilli SB, Packirisamy S, Kumargowda ST, Sridhar VS. 2019. Recent aspects on the pathogenesis mechanism, animal models and novel therapeutic interventions for middle east respiratory syndrome coronavirus infections. Front. Microbiol. 10: 569.
Thanh LT, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S. 2020. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discovery. 19: 305-306.
Wang H, Gan M, Wu B, Zeng R, Wang Z, Xu J, Li J, Zhang Y, Cao J, Chen L, Di D, Peng S, Lei J, Zhao Y, Song X, Yuan T, Zhou T, Liu Q, Yi J, Wang X, Cai H, Lei Y, Wen Y, Li W, Chen Q, Wang Y, Long P, Yuan Y, Wang C, Pan A, Wang Q, Gong R, Fan X, Wu T, Liu L. 2023. Humoral and cellular immunity of two-dose inactivated COVID-19 vaccination in Chinese children: A prospective cohort study. J. Med. Virol. 95: e28380.
Yuan Y, Xu J, Ma B, Chen G, Wang Z, Wang S, Jing N, Zhang J, Wang B, Yan W, Zhang Q, Zhao Q, Li Y. 2023. Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study. Front. Immunol. 14: 1107866.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579: 270-273.
Zhu M. 2004. SARS Immunity and vaccination. Cell Mol. Immunol. 1: 193-198.
Gu J, Korteweg C. 2007. Pathology and pathogenesis of severe acute respiratory syndrome. Am. J. Pathol. 170: 1136-1147.
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. 2020. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil. Med. Res. 7: 11.
Harris PE, Brasel T, Massey C, Herst CV, Burkholz S, Lloyd P, Blankenberg T, Bey TM, Carback R, Hodge T, Ciotlos S, Wang L, Comer JE, Rubsamen RM. 2021. A synthetic peptide CTL vaccine targeting nucleocapsid confers protection from SARS-CoV-2 challenge in rhesus macaques. Vaccines. 9(5): 520.
Inoue H, Nojima H, Okayama H. 1990. High efficiency transformation of Escherichia coli with plasmids. Gene. 96: 23-28.
Jeewandara C, Aberathna IS, Pushpakumara PD, Kamaladasa A, Guruge D, Wijesinghe A, Gunasekera B, Ramu ST, Kuruppu H, Ranasinghe T, Dayarathna S, Dissanayake O, Gamalath N, Ekanayake D, Jayamali J, Jayathilaka D, Dissanayake M, Jayadas TT, Mudunkotuwa A, Somathilake G, Harvie M, Nimasha T, Danasekara S, Wijayamuni R, Schimanski L, Rijal P, Tan TK, Dong T, Townsend A, Ogg GS, Malavige GN. 2022. Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine. Immun. Inflam. Dis. 10: e621.
Kiros M, Andualem H, Kiros T, Hailemichael W, Getu S, Geteneh A, Alemu D, Abegaz WE. 2020. COVID-19 pandemic: current knowledge about the role of pets and other animals in disease transmission. Virol. J. 17: 143.
Liu DX, Fung TS, Chong KK, Shukla A, Hilgenfeld R. 2014. Accessory proteins of SARS-CoV and other coronaviruses. Antiviral. Res. 109: 97-109.
Liu J, Chang W, Pan L, Liu X, Su L, Zhang W, Li Q, Zheng Y. 2018. An Improved method of preparing high efficiency transformation Escherichia coli with both plasmids and larger DNA fragments. Indian J. Microbiol. 58: 448-456.
Liu YC, Kuo RL, Shih SR. 2020. COVID-19: The first documented coronavirus pandemic in history. Biomed J. 43(4):328-333.
Omma A, Batirel A, Aydin M, Yilmaz Karadag F, Erden A, Kucuksahin O, Armagan B, Guven SC, Karakas O, Gokdemir S, Altunal LN, Buber AA, Gemcioglu E, Zengin O, Inan O, Sahiner ES, Korukluoglu G, Sezer Z, Ozdarendeli A, Kara A, Ates I. 2022. Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Turkiye: A randomized trial. Hum. Vac. Immunother. 18: 2122503.
Putra A, Widyatmoko A, Ibrahim S, Amansyah F, Amansyah F, Berlian MA, Retnaningsih R, Pasongka Z, Sari FE, Rachmad B. 2021. Case series of the first three severe COVID-19 patients treated with the secretome of hypoxia-mesenchymal stem cells in Indonesia. F1000 Res. 10: 228.
Santi T, Sungono V, Kamarga L, Samakto B, Hidayat F, Hidayat FK, Satolom M, Permana A, Yusuf I, Suriapranata IM, Jo J. 2022. Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia. Clin. Exp. Vac. Res. 11: 209-216.
Sharma O, Sultan AA, Ding H, Triggle CR. 2020. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front. Immunol. 11: 585354.
Skariyachan S, Challapilli SB, Packirisamy S, Kumargowda ST, Sridhar VS. 2019. Recent aspects on the pathogenesis mechanism, animal models and novel therapeutic interventions for middle east respiratory syndrome coronavirus infections. Front. Microbiol. 10: 569.
Thanh LT, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S. 2020. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discovery. 19: 305-306.
Wang H, Gan M, Wu B, Zeng R, Wang Z, Xu J, Li J, Zhang Y, Cao J, Chen L, Di D, Peng S, Lei J, Zhao Y, Song X, Yuan T, Zhou T, Liu Q, Yi J, Wang X, Cai H, Lei Y, Wen Y, Li W, Chen Q, Wang Y, Long P, Yuan Y, Wang C, Pan A, Wang Q, Gong R, Fan X, Wu T, Liu L. 2023. Humoral and cellular immunity of two-dose inactivated COVID-19 vaccination in Chinese children: A prospective cohort study. J. Med. Virol. 95: e28380.
Yuan Y, Xu J, Ma B, Chen G, Wang Z, Wang S, Jing N, Zhang J, Wang B, Yan W, Zhang Q, Zhao Q, Li Y. 2023. Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study. Front. Immunol. 14: 1107866.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579: 270-273.
Zhu M. 2004. SARS Immunity and vaccination. Cell Mol. Immunol. 1: 193-198.
Diterbitkan
2023-07-23
##submission.howToCite##
DEWI, Ni Putu Sutrisna; MAHARDIKA, I Gusti Ngurah Kade; SUARDANA, Ida Bagus Kade.
Studi Pendahuluan Pengembangan Vaksin DNA Menggunakan Gen Nukleoprotein Virus SARS-COV-2.
Buletin Veteriner Udayana, [S.l.], p. 1002-1011, july 2023.
ISSN 2477-2712.
Tersedia pada: <https://ojs.unud.ac.id/index.php/buletinvet/article/view/104216>. Tanggal Akses: 15 oct. 2025
doi: https://doi.org/10.24843/bulvet.2023.v15.i05.p37.
Terbitan
Bagian
Articles
